SFA Stock Overview
Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, infusion medicine, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Sopharma AD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | лв6.10 |
| 52 Week High | лв7.76 |
| 52 Week Low | лв5.20 |
| Beta | -0.053 |
| 1 Month Change | -2.87% |
| 3 Month Change | 1.67% |
| 1 Year Change | 4.45% |
| 3 Year Change | 83.73% |
| 5 Year Change | 87.69% |
| Change since IPO | -1.41% |
Recent News & Updates
Recent updates
Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet
Apr 09
Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching
Feb 20How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?
Feb 05Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?
Jan 22Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet
Jan 06
Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years
Dec 22Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?
Dec 07Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?
Nov 19Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?
Jul 07Shareholder Returns
| SFA | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | -1.0% | -1.3% | 0.3% |
| 1Y | 4.5% | 4.4% | 16.0% |
Return vs Industry: SFA matched the BG Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: SFA underperformed the BG Market which returned 15.9% over the past year.
Price Volatility
| SFA volatility | |
|---|---|
| SFA Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in BG Market | 8.2% |
| 10% least volatile stocks in BG Market | 2.1% |
Stable Share Price: SFA has not had significant price volatility in the past 3 months.
Volatility Over Time: SFA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 4,721 | Ognian Donev | www.sopharmagroup.com |
Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, infusion medicine, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally. It offers products in various therapeutic areas, such as cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology, and gynecology. The company’s products comprise Carsil to treat gastroenterological disorders; Tempalgin, an analgesic; Tabex, a plant-based drug used for smoking secession; Tribestan, a plant-based drug used for stimulation of the reproductive system; Broncholytin, which is used to suppress cough; Analgin, a generic analgesic; Nivalin, a plant-based product used for diseases of the peripheral nervous system; and Methylprednisolon, a general medicine for cases of severe allergies and life-threatening conditions.
Sopharma AD Fundamentals Summary
| SFA fundamental statistics | |
|---|---|
| Market cap | лв1.01b |
| Earnings (TTM) | лв95.21m |
| Revenue (TTM) | лв1.89b |
10.6x
P/E Ratio0.5x
P/S RatioIs SFA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFA income statement (TTM) | |
|---|---|
| Revenue | лв1.89b |
| Cost of Revenue | лв1.47b |
| Gross Profit | лв415.51m |
| Other Expenses | лв320.30m |
| Earnings | лв95.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | 0.57 |
| Gross Margin | 22.01% |
| Net Profit Margin | 5.04% |
| Debt/Equity Ratio | 34.9% |
How did SFA perform over the long term?
See historical performance and comparison